Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer

Treatment for ovarian cancer remains challenging despite a high initial response rate to first line platinum-taxane treatment. Most patients eventually experience recurrence and require further treatment. Persistent activation of STAT3 is associated with cancer growth and progression and is also inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ernest S., Wen, Wei, Dellinger, Thanh H., Wu, Jun, Lu, Selena A., Jove, Richard, Yim, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966246/
https://www.ncbi.nlm.nih.gov/pubmed/29849942
http://dx.doi.org/10.18632/oncotarget.24368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966246/
https://www.ncbi.nlm.nih.gov/pubmed/29849942
http://dx.doi.org/10.18632/oncotarget.24368

Ejemplares similares